​
Login / Signup
Hyesung So
ORCID
Publication Activity (10 Years)
Years Active: 2024-2024
Publications (10 Years): 4
Top Topics
Combination Therapy
Metastatic Colorectal Cancer
Top Venues
Yonsei medical journal
</>
This page only lists publications with an associated author ORCID identifier.
Publications
</>
Hong Jun Lee
,
Jae Seung Lee
,
Hyesung So
,
Ja Kyung Yoon
,
Jin-Young Choi
,
Hye-Won Lee
,
Beom Kyung Kim
,
Seung-Up Kim
,
Jun Yong Park
,
Sang Hoon Ahn
,
Do Young Kim
Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma.
Yonsei medical journal
65 (7) (2024)
Hong Jun Lee
,
Jae Seung Lee
,
Hyesung So
,
Ja Kyung Yoon
,
Jin-Young Choi
,
Hye-Won Lee
,
Beom Kyung Kim
,
Seung-Up Kim
,
Jun Yong Park
,
Sang Hoon Ahn
,
Do Young Kim
Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma.
Yonsei medical journal
65 (7) (2024)
Hong Jun Lee
,
Jae Seung Lee
,
Hyesung So
,
Ja Kyung Yoon
,
Jin-Young Choi
,
Hye-Won Lee
,
Beom Kyung Kim
,
Seung-Up Kim
,
Jun Yong Park
,
Sang Hoon Ahn
,
Do Young Kim
Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma.
Yonsei medical journal
65 (7) (2024)
Hong Jun Lee
,
Jae Seung Lee
,
Hyesung So
,
Ja Kyung Yoon
,
Jin-Young Choi
,
Hye-Won Lee
,
Beom Kyung Kim
,
Seung-Up Kim
,
Jun Yong Park
,
Sang Hoon Ahn
,
Do Young Kim
Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma.
Yonsei medical journal
65 (7) (2024)